Trial Profile
A Phase II Study of Gemcitabine-docetaxel Chemotherapy With Anti-angiogenic Therapy for Pulmonary Resectable Metastases of Osteosarcoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Gemcitabine (Primary) ; Rivoceranib (Primary)
- Indications Osteosarcoma
- Focus Therapeutic Use
- Acronyms PROACH
- 29 Oct 2023 Planned End Date changed from 1 Dec 2023 to 30 Dec 2023.
- 29 Oct 2023 Planned primary completion date changed from 1 Jul 2023 to 15 Nov 2023.
- 14 Aug 2022 Status changed from recruiting to active, no longer recruiting.